Health care costs associated with hepatocellular carcinoma: A population-based study

Hepatology

Volumn 58, Issue 4, 2013, Pages 1375-1384

  Thein, Hla Hla ^a,b   Isaranuwatchai, Wanrudee ^c   Campitelli, Michael A ^a   Feld, Jordan J ^a   Yoshida, Eric ^d   Sherman, Morris ^e   Hoch, Jeffrey S ^c,d,f,g   Peacock, Stuart ^d   Krahn, Murray D ^a,h   Earle, Craig C ^b,g  

^a UNIVERSITY OF TORONTO   (Canada)

^b ONTARIO INSTITUTE FOR CANCER RESEARCH   (Canada)

^c ST MICHAEL'S HOSPITAL   (Canada)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e UNIVERSITY HEALTH NETWORK   (Canada)

^f Pharmacoeconomics Research Unit   (Canada)

^g INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^h UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANADA; CANCER REGISTRY; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HEALTH CARE COST; HUMAN; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; SENSITIVITY ANALYSIS;

AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; COHORT STUDIES; FEMALE; HEALTH CARE COSTS; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; ONTARIO; REGISTRIES; RETROSPECTIVE STUDIES;

EID: 84884977723     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.26231     Document Type: Article

References (44)

1. Bosch FX, Ribes J, Diaz M, Cleries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004;127:S5-S16.
2. El-Serag HB, Davila JA, Petersen NJ, McGlynn KA. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med 2003;139:817-823.
3. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 2009;27:1485-1491.
4. elSaadany S, Tepper M, Mao Y, Semenciw R, Giulivi A. An epidemiologic study of hepatocellular carcinoma in Canada. Can J Public Health 2002;93:443-446.
5. Pocobelli G, Cook LS, Brant R, Lee SS. Hepatocellular carcinoma incidence trends in Canada: analysis by birth cohort and period of diagnosis. Liver Int 2008;28:1272-1279.
6. Dyer Z, Peltekian K, van Zanten SV. Review article: the changing epidemiology of hepatocellular carcinoma in Canada. Aliment Pharmacol Ther 2005;22:17-22.
7. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007;132:2557-2576.
8. Okuda K, Ohtsuki T, Obata H, Tomimatsu M, Okazaki N, Hasegawa H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 1985;56:918-928.
9. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005;42:1208-1236.
10. El-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011;365:1118-1127.
11. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012;379:1245-1255.
12. Brown ML, Riley GF, Potosky AL, Etzioni RD. Obtaining long-term disease specific costs of care: application to Medicare enrollees diagnosed with colorectal cancer. Med Care 1999;37:1249-1259.
13. Brown ML, Riley GF, Schussler N, Etzioni R. Estimating health care costs related to cancer treatment from SEER-Medicare data. Med Care 2002;40:IV-104-117.
14. Baker MS, Kessler LG, Urban N, Smucker RC. Estimating the treatment costs of breast and lung cancer. Med Care 1991;29:40-49.
15. Taplin SH, Barlow W, Urban N, Mandelson MT, Timlin DJ, Ichikawa L, et al. Stage, age, comorbidity, and direct costs of colon, prostate, and breast cancer care. J Natl Cancer Inst 1995;87:417-426.
16. Yabroff KR, Lamont EB, Mariotto A, Warren JL, Topor M, Meekins A, et al. Cost of care for elderly cancer patients in the United States. J Natl Cancer Inst 2008;100:630-641.
17. Doyle C, Stockler M, Pintilie M, Panesar P, Warde P, Sturgeon J, et al. Resource implications of palliative chemotherapy for ovarian cancer. J Clin Oncol 1997;15:1000-1007.
18. Evans WK, Will BP, Berthelot JM, Wolfson MC. The economics of lung cancer management in Canada. Lung Cancer 1996;14:19-29.
19. Fassbender K, Fainsinger R, Brenneis C, Brown P, Braun T, Jacobs P. Utilization and costs of the introduction of system-wide palliative care in Alberta, 1993-2000. Palliat Med 2005;19:513-520.
20. Grover SA, Coupal L, Zowall H, Rajan R, Trachtenberg J, Elhilali M, et al. The economic burden of prostate cancer in Canada: forecasts from the Montreal Prostate Cancer Model. CMAJ 2000;162:987-992.
21. Maroun J, Ng E, Berthelot JM, Le Petit C, Dahrouge S, Flanagan WM, et al. Lifetime costs of colon and rectal cancer management in Canada. Chronic Dis Can 2003;24:91-101.
22. Wai ES, Trevisan CH, Taylor SCM, Mates D, Jackson JS, Olivotto IA. Health system costs of metastatic breast cancer. Breast Cancer Res Treat 2001;65:233-240.
23. Will BP, Berthelot JM, Le Petit C, Tomiak EM, Verma S, Evans WK. Estimates of the lifetime costs of breast cancer treatment in Canada. Eur J Cancer 2000;36:724-735.
24. Will BP, Le Petit C, Berthelot JM, Tomiak EM, Verma S, Evans WK. Diagnostic and therapeutic approaches for nonmetastatic breast cancer in Canada, and their associated costs. Br J Cancer 1999;79:1428-1436.
25. Hartunian NS, Smart CN, Thompson MS. The incidence and economic costs of cancer, motor vehicle injuries, coronary heart disease, and stroke: a comparative analysis. Am J Public Health 1980;70:1249-1260.
26. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-383.
27. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613-619.
28. Jembere N, Campitelli MA, Sherman M, Feld JJ, Lou W, Peacock S, et al. Influence of socioeconomic status on survival of hepatocellular carcinoma in the ontario population; a population-based study, 1990-2009. PLoS One 2012;7:e40917.
29. Joinpoint regression program (version 3). National Cancer Institute. http://srab.cancer.gov/joinpoint/. Accessed September 16, 2011.
30. Kim HJ, Fay MP, Feuer EJ, Midthune DN. Permutation tests for joinpoint regression with applications to cancer rates. Stat Med 2000;19:335-351.
31. Wilkins R. Automated geographic coding based on the Statistics Canada Postal Code Conversion Files, including postal codes to December 2003. Ottawa: Health Analysis and Measurement Group, Statistics Canada; 2004. abacus.library.ubc.ca/bitstream/10573/41318/1/msword-pccf4d.pdf. Accessed October 13, 2011.
32. Rosenbaum PR, Rubin DB. Reducing bias in observational studies using subclassification on the propensity scoreJ Am Stat Assoc 1984;79:516-524.
33. Rosenbaum PR, Rubin DB. Constructing a control group using multivariate matched sampling methods that incorporate the propensity score. Am Stat 1985;39:33-38.
34. Austin PC. Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. Pharm Stat 2011;10:150-161.
35. Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data.New York, NY:Wiley;1980.
36. Statistics Canada. Available at: http://www.statcan.gc.ca/estat/estat-eng.htm. Accessed Jan 31, 2012.
37. El-Serag HB, Siegel AB, Davila JA, Shaib YH, Cayton-Woody M, McBride R, et al. Treatment and outcomes of treating of hepatocellular carcinoma among Medicare recipients in the United States: a population-based study. J Hepatol 2006;44:158-166.
38. Davila JA, Henderson L, Kramer JR, Kanwal F, Richardson PA, Duan Z, et al. Utilization of surveillance for hepatocellular carcinoma among hepatitis C virus-infected veterans in the United States. Ann Intern Med 2011;154:85-93.
39. Davila JA, Morgan RO, Richardson PA, Du XL, McGlynn KA, El-Serag HB. Use of surveillance for hepatocellular carcinoma among patients with cirrhosis in the United States. Hepatology 2010;52:132-141.
40. Lang HC, Wu JC, Yen SH, Lan CF, Wu SL. The lifetime cost of hepatocellular carcinoma : a claims data analysis from a medical centre in Taiwan. Appl Health Econ Health Policy 2008;6:55-65.
41. Progress Report on Cancer Control in Canada. www.phac-aspc.gc.ca. Accessed February 25, 2012.
42. Riley GF, Potosky AL, Lubitz JD, Kessler LG. Medicare payments from diagnosis to death for elderly cancer patients by stage at diagnosis. Med Care 1995;33:828-841.
43. Krahn MD, Zagorski B, Laporte A, Alibhai SM, Bremner KE, Tomlinson G, et al. Healthcare costs associated with prostate cancer: estimates from a population-based study. BJU Int 2010;105:338-346.
44. Lang K, Danchenko N, Gondek K, Shah S, Thompson D. The burden of illness associated with hepatocellular carcinoma in the United States. J Hepatol 2009;50:89-99.